Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

THROMBOMODULIN ALFA for Thrombotic microangiopathy: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 5 adverse event reports in the FDA FAERS database where THROMBOMODULIN ALFA was used for Thrombotic microangiopathy.

Most Reported Side Effects for THROMBOMODULIN ALFA

Side Effect Reports % Deaths Hosp.
Drug ineffective 15 20.8% 7 7
Off label use 11 15.3% 6 3
Thrombotic microangiopathy 11 15.3% 1 3
Disseminated intravascular coagulation 9 12.5% 4 5
Blood alkaline phosphatase increased 7 9.7% 0 0
Blood creatinine increased 7 9.7% 0 0
Blood urea increased 7 9.7% 0 0
Cardiac failure acute 7 9.7% 0 0
Gamma-glutamyltransferase increased 7 9.7% 0 0
Weight increased 7 9.7% 0 0
Diarrhoea 6 8.3% 0 3
Sepsis 6 8.3% 2 3
Hypotension 5 6.9% 3 3
Respiratory failure 5 6.9% 5 3
Venoocclusive liver disease 5 6.9% 5 1

Other Indications for THROMBOMODULIN ALFA

Disseminated intravascular coagulation (23) Product used for unknown indication (12) Acute promyelocytic leukaemia (5) Venoocclusive liver disease (5)

Other Drugs Used for Thrombotic microangiopathy

ECULIZUMAB (1,312) CAPLACIZUMAB-YHDP (854) RITUXIMAB (99) RAVULIZUMAB-CWVZ (62) METHYLPREDNISOLONE (56) DEFIBROTIDE (34) PREDNISOLONE (32) PREDNISONE (30) MYCOPHENOLATE MOFETIL (23) CYCLOPHOSPHAMIDE (21)

Related Pages

THROMBOMODULIN ALFA Full Profile All Thrombotic microangiopathy Drugs THROMBOMODULIN ALFA Demographics THROMBOMODULIN ALFA Timeline